Pharmacokinetics NCA
A rigorous noncompartmental pharmacokinetic (NCA) analysis, compliant with international regulatory standards, with the option to deliver your data and results in a CDISC-compatible format — to accelerate review timelines and support confident decision-making.
PhinC expertise
A clear, traceable, and actionable framework, aligned with your quality requirements and development milestones.
End-to-end coverage
From protocol design to expert interpretation, with actionable recommendations.
Standards & tools
WinNonlin, SAS, and alignment with regulatory submission standards.
CDISC Format
PC/PP SDTM: robust structuring, consistency, traceability, and reproducibility.
Health authority interactions
Deep expertise and in-depth understanding of regulatory agency expectations.
Pharmacokinetics NCA
Comprehensive pharmacokinetic (PK) evaluation of your drug candidate. From study protocol development to bioanalytical data analysis and expert interpretation, our pharmacokineticists cover all aspects of NCA PK analyses.
Key studies & scenarios
NCA PK analyses tailored to key clinical studies and regulatory questions.
- Dose and time linearity studies
- Drug-Drug interactions
- Bioequivalence studies
Factors impacting PK
- Impact of sex and age on metabolism and pharmacokinetics (PK)
- Impact of hepatic or renal impairment on pharmacokinetics (PK)
- Contextual interpretation aligned with the stage of development
Quality & compliance
Parameter calculation and PK analyses are performed in strict compliance with regulatory standards.
- Robust and traceable NCA parameters
- Decision-oriented recommendations
- Agency-ready documentation
A proven and recognized foundation of expertise.
The quality of the results is built on frequent interactions with health authorities, in-depth knowledge of submission standards, and mastery of recognized industry software tools.
Technical tools & environment
- WinNonlin & SAS
- Structured and well-documented analytical process
- Clear deliverables designed to address regulatory questions
Key deliverables
- Accurate information, available in a timely manner
- Expert interpretation throughout the development lifecycle
- Recommendations tailored to the clinical and regulatory context
CDISC-ready PK data to support regulatory submission
The preparation of CDISC-compliant PK data is often time-consuming and costly. However, standardization—particularly through the SDTM PC and PP domains—delivers major benefits in terms of clarity, reusability, and efficiency during regulatory review.
Why CDISC?
- Standardizing analysis and reporting of data
- Facilitates data pooling (e.g., future analyses, PopPK).
- Smoother regulatory review
Main challenge
Effectively coordinating data management, bioanalysis, PK/pharmacometrics, and regulatory activities. Without early PK involvement, teams tend to work in silos, leading to delays and inconsistencies.
PhinC approach
- Early involvement of PK experts and pharmacometricians.
- Actionable data analyses
- Compliant, traceable, and reproducible deliverables
Early PK involvement
Align analysis needs and definitions from the outset to avoid silos.
PK SDTM (PC / PP)
Structured datasets with consistency checks to ensure reliable and reusable data.
CDISC-native results
Generate data and results directly in CDISC format to minimize errors.